<SEC-DOCUMENT>0001193125-13-466912.txt : 20131209
<SEC-HEADER>0001193125-13-466912.hdr.sgml : 20131209
<ACCEPTANCE-DATETIME>20131209165523
ACCESSION NUMBER:		0001193125-13-466912
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20131203
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20131209
DATE AS OF CHANGE:		20131209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ORTHOFIX INTERNATIONAL N V
		CENTRAL INDEX KEY:			0000884624
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19961
		FILM NUMBER:		131266139

	BUSINESS ADDRESS:	
		STREET 1:		7 ABRAHAM DE VEERSTRAAT
		STREET 2:		CURACAO
		CITY:			NETHERLANDS ANTILLES
		STATE:			P8
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d640350d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, DC 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): December&nbsp;3, 2013 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Orthofix International N.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of Registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Cura&ccedil;ao</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>0-19961</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>N/A</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>7 Abraham de Veerstraat</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cura&ccedil;ao</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>N/A</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: 011-59-99-465-8525 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (<I>see</I> General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;5.02. <U>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers</U>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;3, 2013, the Board of Directors (the
&#147;<U>Board</U>&#148;) of Orthofix International N.V. (the &#147;<U>Company</U>&#148;) increased the size of the Board from eight to nine directors and appointed Anthony F. Martin, PhD to the Board. The Board has determined that Dr.&nbsp;Martin
is an independent director under the rules of the Nasdaq Stock Market. There are no transactions involving Dr.&nbsp;Martin requiring disclosure under Item&nbsp;404(a) of Regulation S-K. Dr.&nbsp;Martin will receive the Company&#146;s standard fee of
$60,000 per year for non-employee director service, and has been granted options to acquire 30,000 shares of common stock pursuant to the Company&#146;s 2012 Long-Term Incentive Plan (vesting in 1/4th increments on each of the first, second, third
and fourth anniversary of his appointment pursuant to the Company&#146;s previously filed form of non-employee director non-qualified stock option agreement). Dr.&nbsp;Martin has been appointed as a member of the nominating and governance committee
of the Board and the compliance committee of the Board (which is a newly formed committee of the Board comprised of independent directors Maria Sainz, Guy J. Jordan, PhD and Dr.&nbsp;Martin). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;7.01. <U>Regulation FD Disclosure</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;3, 2013, the Company issued a press release regarding certain of the matters described in Item&nbsp;5.02. That press release
is furnished herewith as Exhibit 99.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information included in this Current Report on Form 8-K under this Item&nbsp;7.01 (including
Exhibit&nbsp;99.1) shall not be deemed &#147;filed&#148; for the purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;<U>Exchange Act</U>&#148;), or otherwise subject to the liabilities of that section, nor shall
it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. <U>Financial Statements and Exhibits</U>. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Exhibits </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Press Release, dated December&nbsp;3, 2013.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Orthofix International N.V.</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jeffrey M. Schumm</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jeffrey M. Schumm</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Administrative
Officer, General Counsel and Corporate Secretary</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: December&nbsp;9, 2013 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated December 3, 2013.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d640350dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g640350g70n78.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Orthofix Appoints Dr.&nbsp;Anthony&nbsp;F. Martin to its Board of Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LEWISVILLE, Texas &#150; December&nbsp;3, 2013 &#150; Orthofix International N.V. (NASDAQ:OFIX) (the Company) today announced the appointment of Anthony F.
Martin, PhD to its Board of Directors, effective immediately. Dr.&nbsp;Martin has more than 25 years of international experience in managing life science businesses in both executive and non-executive roles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Randy Thurman, Chairman of the Board of Orthofix, commented, &#147;Coupled with the recent announcement of Kathy Regan and me joining the board,
Dr.&nbsp;Martin&#146;s addition marks a new era for Orthofix. In addition to the revitalized board, Brad Mason, Orthofix&#146;s CEO, rejoined the company earlier this year and has put in place a seasoned and motivated leadership team many of whom
are new to Orthofix or their roles. In addition to resolving the financial restatement in a timely manner, we are focused on reinvigorating both product and clinical development strategies, establishing leadership in our strategic business units and
creating long-term value for our shareholders.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Martin has a Doctorate in Immunology from the University of Manchester Medical School and a
first class Honors degree in Applied Chemistry from the University of Huddersfield. He began his career with Proctor&nbsp;&amp; Gamble UK before moving to Amersham International, subsequently GE, in marketing and business development roles. He has
significant experience in fundraising and building medical technology companies, including in chief executive officer and chairman roles. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Anthony
Martin PhD </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Martin has more than 25 years of international experience in managing life science businesses in both executive and
non-executive roles. He is currently the Non-Executive Chairman of Immunodiagnostics Systems Holdings plc, Sphere Medical Holding plc, and Phico Therapeutics Ltd, and a Non-Executive Director of Abcam plc. He gained a doctorate in Immunology from
the University of Manchester Medical School and a first class honors degree in Applied Chemistry from Huddersfield University. Dr.&nbsp;Martin has previously served as chief executive officer at a number of international life sciences and diagnostic
businesses including British Bio-Technology Products ltd, Celsis International plc, AZUR Environmental, the molecular biology division of Invitrogen Corporation, and Molecular Probes Inc. He has also previously served as the Chairman of NeuTec
Pharma plc and Molecular Insight Pharmaceuticals Inc. and as a board member of Prelude Trust plc and Invitrogen Corporation. In addition, he previously served on the scientific advisory Board of Agilent Technologies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Orthofix board believes that Dr.&nbsp;Martin&#146;s extensive experience as an international operational CEO, combined with his deep knowledge of the UK
institutional shareholder base for medical companies and UK financing matters, will add significant value to the board as the </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company seeks to grow its UK and European operations and market presence. The board also believes that his
experience serving with both UK and US public companies will bring added depth and a cross-border perspective with board governance matters. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>About
Orthofix: </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orthofix International N.V. is a diversified, global medical device company focused on developing and delivering innovative orthopedic
solutions that drive value for patients, surgeons, and providers. Orthofix&#146;s products are widely distributed around the world to surgeons and patients via Orthofix&#146;s sales representatives and its subsidiaries, and via collaborations with
other leading orthopedic product companies. In addition, Orthofix is collaborating on R&amp;D activities with leading research and clinical organizations such as the Musculoskeletal Transplant Foundation and Education Foundation and Texas Scottish
Rite Hospital for Children. For more information about Orthofix, please visit www.orthofix.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Contact</U>:</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark Quick </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director of Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">markquick@orthofix.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">214-937-2924 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g640350g70n78.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g640350g70n78.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`0@&H`P$1``(1`0,1`?_$`,@```(#`0$``P$!````
M```````+"`D*!P8#!`4!`@$!``,!``,!`0````````````8("0<!!`4"`Q``
M``8"`0,"`@,("PT&!P```0(#!`4&!P@`$1()(0H3%#$B%4$C%K=XF#D:43+5
M-K:7USA8&5EA,]1UM59VEM875W>X0E(D-&0W-565)L<8:!$``@$#`@,$!P8#
M!@<```````$"$0,%!`8A$@<Q05%A<2(R0E(3"(&A8G(S%)$D-+&"(U-$9,&B
M8Q46-C?_V@`,`P$``A$#$0`_`-_'`/KNW;5@U<OGSENR9,T%73MX[63;-6K9
M`AE5W#EPL8B2""*11,<YA`I2@(B/3GZA"=R:MVTY7)-))*K;?!)+O;\#\SG"
MW!W+C4;<4VVW1)+M;;X)+O90_NSY\M9-=QEZ3@5-OLGE=I\=H9:OR/RN**Z_
M)\1/K,W9`B_X0J-ER_7:Q!5P,'4IG*)N6"V)]/&ZMR\FOW#7%XAT=)QKJ)K\
M-ITY*_%<I3X)%<]__4CM':_/H-NTRN8C55A*FG@^SUKJKST?NVZI]G/%F37:
M/R,[@;?3CN1RYEV<1KJIERQ^.*2X=5''<0T6,4P-$J]&N0^UCD*0I1<R*KQT
M<"_64Y<':73/9>R].K6&T=MZGAS7KJ5R])KOYVO5_+!1CY%+-X]5-[[XU#NY
MK6W5I>-+%INW9BGW*$7ZWIFYR\9,AA$3$S7Y!M+P,M)0DLS."C.3B'SF.D&J
M@"!@4;O&:B+A`X"'TE,`]>3B_9L:FV[.HA&Y9EVQDE)/R:=4R`V-1>TMU7M-
M.=N]'LE%M27FFFFF6QZI^:[>+6>3BV<WD!QGS'#91)-_1,MN5IA]\B4P]Y*_
M>^T]JAGI2&'X8K*O&O=^W0/Z=./[NZ%["W39G.QIUCLFUZMW3I15?QVOTY+R
M2C+PDCM6S/J`Z@[3NPMZC4O)8I44K.H;DZ?@O?J1?I<H^,&;/M'-_L"[[8[4
MN.)95:-L\$FT3OV,+"HV1N='?NBB!`>MT3F2E(1TJ0X-))MW-W`%Z#\-4#)%
MH_OWIUN'I[DEHLQ!3TEQOY-^%?EW4O!^[->]"7%>:HW?3I]U*VYU'Q?[["S<
M=7;2^=IYT^;:;[*I>U!\>6<>#['258J<'($=!#@!P`X`<`.`'`#@!P`X`<`.
M`'`#@!P`X`<`.`'`#@!P`X`<`.`'`#@!P`X`<`.`'`#@!P`X`<`.`'`#@!P`
MX`<`.`'`#@!P`X!\:WQO@J_+BF"_PS_`%8IC(@MVC\,52D,4YDP/T[@`0$0^
M@>>8TJN:O+7B>)5H^7VN[TD`-BM"&FWT>[@=A=@LWNJ,Z'J7%>(YV)Q5CHQ.
MXJA"SS1K#SECN:S=0OU#2<BJ@`_6*@0>G;T7;/4.>S+BU&V\;H%D%_J-1&6H
MO?W&Y0A:3[^2"?C)G-=S].([VA+3[FR>0>.?^GTTH:>Q_?7).=UKN=R;7>HK
MA2IC,WML=<K`RE$M><[9!H-OCFJ2I(2_JP60J^"[DAS,4Y0L6PK5BAVCP$#]
MBI3+FZ`82D.!>WG8<']4&YM-.#W)C]/J-%)OUK//9GP[>7F<X2:KV<.ZK1Q;
M/_2GM75VYK;.1U.FUT57EO<EZ%7V<W*K<XIT?'UN]I.AF9W!T4V0T=N#>K9V
MIGR,9+JKDJ=_KZRDQ0+BFW'N/]C3Q44?@2*:0@=1B[3;O4BCU%/MZ&&TVR]_
M[8W[HGJ]OW^:]!+YEF:Y;MNOQ0J^'A.+E!^->!4G?/3C=73W7+2;AL<MF;?R
M[T'S6;E/AG1<?&,E&:[XI49#[DS(&'`)"ZM;-Y1U!S74<YXDE#,K%6G14Y.)
M755+#7"LN5$PFZC86Z9@!S$R[8O;_P!Y!8$UDQ!1,HA'=V;6Q6],%>V_F(*6
MFNKU9>];N+V;D'W2B_L:K%\&R5;,W?E]C[@L;@PT^746I>M'CRW(/V[<UWQD
MOX.DE2233(_6#8J@[7X*QYGK&SD5:U?81)^9@LJDI(5Z:0,9I/5B6!$1*G*0
M$LBJV5#H`'[`.7ZARB.8>Z]LY'9^X-3M[**FJT]RE>-)Q?&%R-?=G&DEX5IV
MHU8VCNC&[SV[I=QXIUTFIMUY:IN$UPG;E3WH23B_&E5P:.^\CI)`X!XF_P"2
M\<XHKSFVY1OU,QQ5F?7YJR7JSPM3@D!*0R@E5E9YZP8E/V%$0+W]P]/0.`5;
M7[S\>&_&SUQ'V7R"8'=.FJATER4M_9,EIIJIJ`DHG\QC>NVMN<Y%!Z"!3B(=
M!^X`]`.<)>Y,\(RRJ:)-]:.!U3E3**N,\]()`8X@4!477Q2FBB0!'U,<Q2E#
MU$0#@$L\*^7#QD;$2#>'P_O/K9;)QWV?*UY;)L#6;&X%3]H5*O6YQ`S1SG$.
M@%!#J)O3IU].`6'I*I+I)+H*IK(+)D5162.51)5)0H'3524((D434(("4P"(
M"`]0X!\G`#@$8LM[KZ>8$7=-<U[2Z^XJ>L3'(\CK[EZAUB3:&3Z?$*YC):=;
M/T1)U]>Y,.G`(V_US7B9_M'=,OSA,;?N_P``]!6O+AXNKC)I0U8\@^GLS*+F
M*5)DSV"QF98XG'M*!0/8B!ZF_N\`G54KI3K]"M[)1;96KI778B#6>J4[%V.%
M<B`%,(-Y2'=/&*P@4X"/:H/H(?L\`B]G?R&:*:O75+'&QNW>O.#[\O#,K$C3
M<H96I]+LBL#)*ND&$P2(G95F]-'/%F2Q4U0)V',D8`'T'@'%OZYKQ,_VCNF7
MYPF-OW?X`?US7B9_M'=,OSA,;?N_P`_KFO$S_:.Z9?G"8V_=_@!_7->)G^T=
MTR_.$QM^[_`.F8?\F?CRV"R'`8DP;NMK+EO)]J^T_P`&J!C[,=(M5MG?L:)?
M3TM]E041,.I!]]G0L8X=+?#(;X;=`YQZ%*(@!Y&U>7'Q>4>S6&EW'R`ZCUBV
MU*;E:U:*W.9VQ[&S4!8(-\O&S$++QSJ<3<L).,D&RB*Z*A2G35(8I@`0'@$D
M]?=JM:ML*[.6W67.V*L]U>LS1:Y8;!B>[0-XB(6?.Q;2A8>3?P#UZW9R)HYX
MDN"1S`?X2A3=.@AP#OW`/"9-RACG"]"L^4LMW>KXVQO2XX9>W7FZ33&NU:MQ
M8+HMAD)J:DUF[".:`X<$)\14Y2]QP#KU'@$"_P"N:\3']H[IE^<)C;]W^`6%
MTZXU3(53K=[HMBA[=2[C!QEFJEIKT@VEH&Q5Z:9HR$1-0TFS45:2$9),5R+(
M+)F,11,X&*(@/`/V9"081+%W)RCYG&QK!NJ[?2$@Y19L635`@J+.7;MP=-!N
MW13*)C'.8"E`.HCP"M;,'F:\5>!I-W"9/WTUNAYR/'M?0<+D&/O4TT-U$.UQ
M$4(MGD43=0$.AD@'J`_L<`C4/N4/"(`B'_[Z4KT'IZ8OS\(>G[`AB80$.`=C
MQIYV?$#EM^SBZ9Y`=>PD9!1-)DSN-CD,:+N5E>GPT4R9*B:D(KGZ]`)^VZ^G
M3KP"T*IW&H7V#9V>C6JMW2M2`&,PL-3G(RQP;X"B`&%G+0[IXP<@41]>Q0W3
M@'I.`'`.5Y)SIA/#38KS+V7\88M:J)"NDOD.^U:F)K(E$0%1$;%*QWQB=0$.
MI.OJ'`(;2OF#\5<&]4CI;R(Z<,'J0`*C9?8/&@*$`1$`$0+83!ZB4?N\`_-_
MKFO$S_:.Z9?G"8V_=_@!_7->)G^T=TR_.$QM^[_`.U91\A>BV$JKBV\9?VZU
MYQG3LX5U>W8=L]WRM3ZY!Y.J[9O#NW%@H\E)RK=K9(A%K8&*AG#4RB8$=I#U
MZ*%Z@<]I/ED\8^2+?6L?T#?C4VY7BYS<=6ZG4ZWG+'\O8+'8)=RFSBX:&BV4
MVL[D)*0=JE3113*8ZAS```(CP#T^8O)=X^->K_,8JSMN?K;A_)5?38K3=$R/
MERG4^U1B,FS1D(Y=W"SDHR?)-WS)<BJ2G9V*$-U*(\`_%QSY4_&MEZ\5G&>+
MM[M4K]D*Z2B$'4J95<XX_F;)9)ER!A;14+$LIQ5Y(R+D2"":*13**&]"@(B`
M<`GUP`X!!+*OE!\<N#+]8L5YCWBU:QGDFHN465IHMTS908"TUUZNU0?),YJ&
MD)M%]&NS-'*:@I*D*H4IPZ@'7@'SXC\F_CQS[?X+%6$-U-:<M9*LYW1*]1,=
MY>IENM4P+%FO(/3,(2$E7C]=-FQ;**JG`G:FF01,(!P#K5<V]U;M]_+BRK[`
MXEG\A*R#N(:U6+O$"\DY"78"H#Z'BBI/#(RTNS%%3XK5L=5PG\,_<0.P_0#]
M38'9S`^K5+<7W/.3*UCR`3(L+(LN\`TS.N$2";Y"N5]J"\U/R!QZ`"35!42B
M(";M+Z\D&W-J[@W;KEC]O:6[J=0Z5Y5ZL4^^<W2,%YR:\B.;EW;MS9^@>2W'
MJ[6ETR3IS/UIM=T(*LYR\HI^9E0W<]Q1DB]_:U$TMK;C%M74^.R5R_<V;%_D
M.40,"J1EZQ63_.0E/34(<!(LY,^>%Z`8H(&]`MUL3Z:L7C^3(;YNK5ZO@UI[
M3:LQ?A.?"5SS4>6/YD4VZ@_5%D\A\S&["M/1Z1U7[FZE*])<56W#C"UY-\\N
M]<C)J^V\N]GR%C';BTWFU3ESNLQF:I2<_8;-,O9R?DCO*<K\%R_?2"J[I0#J
M(J@3J;M#H)2@`%Y!OJ=T&DQN5PVDQ]FW8T,-#<C"$(J,(TN<4DDEV-5)_P#2
MMD=9E,/FM9D;T[^0GKK<ISG)RG*MMT<FZM\4Z59?GG?`^+-E,7VC#V9*G'V^
MCVMDHV>L'J1/FH]V!#@RG(-]VF<0\_$K'^*U=HB55%0/I$HF*->-O[AR^U\M
M:S6$O2LZ^S*J:[&N^$UV2A)<)1?!HLEN+;F'W7B+V#SMF-_'WHT::XQ?=.#[
M8SB^,9+BGY5%TN_VDUZT.V&G\.VE5S-59Z0]DQ9>%&PMT+K173A5)B\4`O5!
M*<B52&:22!1$$W28F+][43$=+>G>^\?U!VU;S>D2MZN+Y+]JM?E74JM+OY9>
MU!OMBZ/BFC+CJ9T_R/3C<UW":MNYHY+GT]VE%=M-T3\%./LS2[)+AP:;A/R<
MG.P'UYY7!GDU`>VUVHDX/)>4-0K#)**UNZPCK*V.FJQS"2-MM>^38W*/9`8>
MTA)V`50=G('_`&X\Q@#ZQQY5/ZGMI6=1B])O/31IJK$UI[S7O6YU=IO\DZQ7
ME.G<BX'TI[QO6,IK-DZJ==)?@]183]VY"BN17'WX4E1?Y=>]FQ'E*B\I0!Y\
MO-I6O$;@N"BZ)%0M[VVS8VDT,.4J;,L>OU6#CS`TFLKWALU.DY=P4(\5*W8,
M"J(FE9`1)\0J*#DQ0%5>U>Z^U6[V0W^3MI,WWW,-I>N5UFA++,N#UZO(KJF4
M",J-2:"WK54B4>H%3;1[5NF``'4!'U$"[S1/VJGDNW.HE>RQ:FE!U4QK;(UK
M-5AYG-U.HWN?A7R*3EA+,L:UN)DYZ,9R#98JK?[7/%G62$#E*)#$,8"R6P^R
M#V9;1"B]4WHP5-3P)=R4;8,87^LQ*BW8`_#/-1TM;'::8G].\&!AZ>O;]S@&
M;?R->'_>7Q<3\.TV@QF@A1[2]7CZ9F*B286W%EH?H$.N>*0L*+=HZA)\&I!6
M"/E&S)V=(ICID4(0QP`DMXI?/QNOXRKY6(LMZLV<-732;5&\:\W^?>S48A`*
MJD)(/<5R\LL[=8ZM#5#JHW^5,$:X5#M=-E"F[B`-K-=]D\0[1Z^XVV=Q#:&T
MUB+*-(97ROS[H2,3,XE=N=61:3J2J@EB9:N.VZ[211.;_P`*Z;*D$1[>O`%G
M'G`]RALUN%F#(>"=/<FVG!&GE0F96H1TKCV8>UK(&>"1;M5B_N5JMT4LVFHR
MGSBR!CQD*R602%B)#O1754$B(&?_`%1TIV]\@F4'>.]7L.WS.E[["2EF>QH$
M^R:\S=+?!":N]VL#QC7:XT75`0(K(/4C.#E$B0*'^KP"^Z"]GAY=I6(5D),=
M9:T_!L1=""E,QO7C]18Q1$S15S!TV5BD%DQ]!,#@Z?7Z##P"'.XWMN/*UI/B
MNS9MR-AFKWW%U(BW<[>+3AB^Q5\-3Z_'H&<R-AG*ZHC#6M.#C&Y!4=.D&*Z+
M5(#*JF(D0YR@5UZ6>0+;3Q^Y4@\LZNYBM5`E(N0:.9BJIR;QYCR\QR#DCAQ7
M[W2%W'V%9(>0(!DS@JD#A$#B=!5%4"J`!L)\@/BDV^]Q=,:P>475:3P53,=9
M@U,QI`3E2R'=K%$3U8R73[!=XW(M?1)'U*<1>P\-9SKMFKDRI%%TDN\Q`ZAU
M`K^_4T_*G_GSJA_&9<?Y..`46^2+QNYY\7>>(K7G8>5H$Q>)B@0F1FKK'$Y(
MS\$6"GI&9C&:*SR3AH-RG($<P:W>G\$2@42B!AZ^@'.M$=*LL^0O:#'FIF$)
M"H1F2\EM[>Z@'M[E7D)6$DZ539Z\RP2$BPC9=VB=2'KJY40(W4$ZPD+Z`/4`
M-"_ZFGY4_P#/G5#^,RX_R<<`M(\+WMGM_P#Q^^237?;3-=JU[DL9XK_WH_A(
MSI%XLLS9UOPRP]?J'%?9D<_I40T7$DS9VYE1.X)VH%.(=1``$#%=Y&?T@>\/
MY7&Q?XW+=P#>[[)+^8[M[^5:Q_%#1^`;3^`4Y>X(_0S>03_D<K_"VL<`3*<`
M<B8FW9PYX\_!CJSM9G!VX+3L=:8Z[_(0,:=N6>N]NEL:UB/JE&K9')BI'F;'
M+*D2*8W4C9$%'"GWI$X@`LR\EOFQWG\G5YG'V6<G3E&PLH^<#4-<<=S<G!XN
MK<3\43,D9IDT5:K7^>(D4HK24Q\PJ93K\$C=+M1*!]CQK>#K?ORDHN;1K_CZ
M*K.&XR55A9;.V5I-S4L:$E&JB1)"+@'*,?*3USE(T%0^92B&+PK4WU5SI&$H
M"!H/CO9`[(*Q!5I;>["+*>%(1/&QV*+Y*1!5^T.U,LVYGXAX9(3>@G&/`0#U
M[1^C@%1?D/\`;-^2+Q\T.?S'(05*V)PG56RDA:[]@F0F9B0IL.D0RCB<MU%G
MX:%M4?",DP`73UHB_:-`ZG65(D7XG`*O-+O(EN-X_,A1V1=5LXW''+IJ\0<R
M]0)(N97&MR;)+%65B[KC]^JK6K"Q<@!BB95`'*0',9%5)3H<`&S'A5\M^//+
MEJR&5(^(943-^-W[&G9_Q:U<JN6M:M3AD9U&V2LK.3&=NZ+=6R"J\<=43+-U
M$7#14QU&XJJ`45^YN]P)E/3>VH:%Z26E*H9N>5MA8\ZYKC@0=S^,(JPH"XKE
M!HH.$5VD9=9B*,60?21@.M',UFY&X%76.H@`OQI=.VFWKSE%TRH1^7-G<_Y(
MDUQ9,COI_(-YL#Q3[\^D'\G+.WKE%DV3#XKIX[73;-DBB=50A"B(`:$,9>S]
M\N=YBX^4MC37C$8OD6JQXBZY;/*S<<#@H&53D&]"K=NCDUVH#T.1-VK]8!`!
M'[H':/U+;R6?\<=0O];\H?R5\`/U+;R6_P#''4+_`%ORA_)7P#U/NJL'6G6;
M6'P:Z\7B0A):Y82UCRYB^SR=;5=K0#^=I<)K1`R;N&6?M63U6,7=L3&1,JBD
MH)!`3%`?3@&=KQ,_I.=!ORL\&?C`@^`-"/.;X1,4^6?"2DK74*_0-PL:Q#@V
M&LN.&PMT)MJB95X?%V1G+1,SF0I<TX.;Y9P8JRT,\4^81**9W*"X"E#+>)LR
MZK9JM>*,I5NTXFS3A^WJ1<W#O?FX6Q5BS0+PB[.1C7S<Z2H%^(FD[CY!JH*2
MZ)DG#=0Q#$.(#+[VW_N`6&_5-AM.]M+,R8;G4&"%.HW*1419(;)TZ%;_`%Y0
M.A$FR65J^P3*,LU((#*HD%^B7N!TFD!T#W%7GR@_&YCY[K+K5/Q,YN]DF`[S
M/$#-)5GKO3I=N((W>Q-#"L@-ZEVRG?`1JY!`I1^><$%`J";D!7[2J5FC:C-D
M-2Z9#W',N=<VW@6T='-0?62Y7J[VJ15=/'CMPJ99V\>OGKA5R\=KG[$R`HNL
M<I"G.`#.303P.H^,'QN9\?Q<:ODW?_,V(UF^5[=0'!AL,/3E7;.1N&","RH@
MW>L7CNGE>LPD$#(.IJ<,BH`D23:)I`0U>U5S,9MR+:*_;T++K3D2^[;0NF>(
M<-9#DI&^M,CIXTPY`Z<TLN#%<B/$,8U:MY&;S$O#.HJH0U@IUE@')IM5LP65
M.H!3GM9FC(F?-@,I9"R9:9RT33Z\6I%@$S*.I%"!B4)MX@Q@H-!=06\5$,&R
M)2)H-R)I%`/HZB(CJ[M'!8W;NW-)C<79MVK$=/;;Y8I<\G!-SFUQE)NK;E5F
M0F]-P97<FY-9D\K>N7=1+47$N:3:A%3:4(I\(QBJ))41'KITY)&Z]O:10TX^
MV9RZUA,S['8/>N4T5+]1*OD.$0.;H9T^Q_+/(6522`?052Q]R34$`]1(F8>G
M0O4*K?5-A9W\'C,]"+II]1.S)^"O14HM_;:I]I;WZ2\Y"QG,IM^Y*DM3IK=Z
M"\79DXRI]EVOH1L@Y2<O24T><74%KLWIC9[I!QA7.4-=4I#*=0<(I"9X\KC%
MJ4<AUSJ0.XZ#^MMC.RD'T^98)?1U'G;N@N])[5WQ:T.HG3$Y-QL7%W*;?^#/
MTJ;Y:_#-G"/J$V1#=NPKVNT\*Y?&)ZBVTN+MI?XT/0X+GI\4(F`,A@.4#!Z@
M/J`_L@(=0'FB;5#-%JA_KG@\$^?%K?G6-O(7J98FS@S9-WEJ'J,B<#"`&B;T
MW>5"23.`"`&*9M,CZ#Z=0#G/.K..AE.F^8TTU5QT<KD?S6FKD?OB=-Z-Y&6*
MZFX;5Q=$];&V_P`MZMJ7W38R8YF$:LB@[W/V>)W-_F6V@82+MPK!X3+1<(5!
MBJ<XI1D74J=$24RF@01[2@_N=@E'0B`!U^.`#UZ`/`/Y[9/3VC;B>6/#L-DZ
M&:V3'V$*W:]A)VN2+=!W%3\I0`C6E(CI5JX`R3J/1O,_'/543%,1<C,4S@)#
MF`0&^7`#@$-_(+JICW=?37876S),$UG(7(F-;*VAC+(I'=P%VC8UQ*4>UPRZ
MI#F93-<M#1JZ15)T$>PQ#=2'.40$;DE'N8F1D(IX4"/(QZZCW9`'J!'+-=1L
MN4!Z!U`JJ8AUX!N9\+6XMZJ7MH/+A6D)5XW=ZY,\EQN.I0BRQ7$$RV%HL=&I
MM(]0H'!$L?;WK]\F4`Z`L\.)A`#>@&%G@#'[P8^7#P@^.#QW87PY8-C(:GYV
MM,8;(NQRZ&)\KR4O)94L*JRKB,E)Z+HKQM*-J=#?+13,$G"K9-)L8R7JJH)@
M+@OUGKPF_P!,5'^*+-7\GW`*OO*)[J_QPSFH6PN%-6I'(.?,L9GQ/D#$4$J-
M!GJ30*VED2K2]1?6FPSEO3A9)XVAF,HHNDS9,UU72Q2)G,BF8RA0%HS9LX>.
M$&C1!9T[=+)-FK5LD==PY<+G*DB@@BD4RBRRRA@*4I0$QC"``'7@#HSP9:U9
M!U)\4NF^$LKQCF"R/#XX>6JWUUZ0J3ZLR>2+58,A)UJ12+U%"5@6%F1:O$Q$
M3)NTE"C]'`+9N`*W/>6?I4Z/^2EC3^%^1>`0]]K+^G`U#_Q5L#_TZ94X`WEX
M`<`1I^1G]('O#^5QL7^-RW<`T1>W9\]&H_B9UPSMB/8:BYNM5DR;FYOD>"=X
MOK]4F(EO!I4.N5D6\BM8+A6W",C\_$*&[2)J$%(Q1[@'J'`-"/ZZ%XR/^#FW
M?^I&-?Y4^`0'\HONH-!-U?'_`+1ZL8QQ?LO#7[-6.#U&KREOJ=#85EG)&G(:
M2!:8=QF0Y9^@T!&/.'5)LJ;N$`Z=/7@"_C@&RCW%V>)UEXL_!-K.P=N&U>L&
MK-.S79FJ:BA$921K6)\=TJH_'(7HFH6*3L,L8`-U^LX`>@"4!X!DJP;C)[FK
M-6(L.QRYFK[*N3:)CEH[(!#&:+W2SQ=<3=E*H()F%L,C\3H(]![>`/1-?L%X
MYUEPEB[7_$<`RK..,1TN#I%4AV*";=-*.A&2;8SQR"0`"\G+.04=O%S=5'#M
M=14XF.<PB!V'@'UWC-I(-'3!^U;OF+YNNS>LGB"3EH\:.4C(N6KILL4Z+ANX
M1.8AR'*)3E$0$!`>`);O.#J74M)O*/MK@7'D:$+CB-OC6[8]A2_WF"J.38"*
MOT=7V90(0"1M>5L"K%H'J(-6Z?41'J/`+:?9RYQL>/?*=.X?9N5AJNP.ON08
MB=C0$_RQIO'!F&0*U,'(7ZOS,<TC9-LF8?H(_4#Z3<`H8\F&8IC/_D)W2R].
M.EG3RY[+9?=-C+&[S-X.,NDM!UJ.(/0/O$57(MJU2#[B:)0X!?9[9_R=>,_Q
M=Q>Q^3-M7U_9;`Y-DZU3*1(U+&,G=DX7$D.R^V)=LWEF;I(D<XLUM<D%VB!0
M,=.+;B)A#T`#5E^MW>&K_/O/?\1%B_P[@!^MW>&K_/O/?\1%B_P[@%N/CO\`
M)SJMY0\=WS*.J,Q=)FIXXNB-!LR]UIC^EO4K"O!L+"FDS9OUECO&OV;))"*I
M1Z`<1+T].`8Z/?(_ON\;/^CFU?\`E/7W@&2_Q,_I.=!ORL\&?C`A.`.[^`9S
M//KX(*!Y5\6GRKBQ.*HN[>+*T]0QW;%"MV$)EN$9D5>-\4Y*==I.U!9SW!#3
M!Q,I$N%3%/WM55"E`52RD3G?4'/2L;+,KO@O87`M^14.W<INJ[=L?7ZH22;E
MJNF/HH@\8/FY%452"=%=,2G(*B1P$P'U9^>S=M?G%_/SKR[YOS[G.]_'=.#)
MOK1><A7VVR14D4&S5LFL[?R,B^<$1;MT2`1,O8DD0J92E`!H][>/P)UGQEXX
M:;$;`Q439=X<GUM-.47$$G['`-1FFR*SG&M5<@=5LO9WA1`M@E4?[Z<OR;<X
MMB'4<@:>>`>+88WQW%6J0O<70J7&W>7(=*5N3"K0;.U2:2G3XB<A86[%.7>D
M4Z!W`HL8!Z>O`%E.W.,GN&MI=@\6OTSIKTK+=VB2"IW=R[,9MT\CG91,(F.B
M]CW:2R9A]3$.`_=YJ[LW*PS>T<=EK?LW]':EZ'RI27I4DT_09";YQ%S`[PR>
M(NIJ5C6W8JOP\[<7Z&J->3(\<D9%"46EFR<MJ)M#A_8&,!RNTHUI0_"N.:&$
M%IJBS22D)=(DA?0#KNJ\^7%$!]`<$3'[G(IOK;%G>>T];MR[13U%E_+D_=NQ
M]:U+T*:5?*I-.G^[+VR=X:'<=FKMZ>\OF17O6I>I=CZ7!RI7OH,R*3<ZSD6G
MUB^TN89S]2N4#%V6MS3!4JS.3A9EFB_CWB!RB(=JS9<HB`_6*/4!`!`0YEKK
M]#JL9K;N.UT)6]98N2A.+X.,HMJ2?H:-9L?K])E=#9R6@N1NZ*_;C<MS7%2A
M-*46O2F?LRD:QFHR1AY-LD\C99B[C9!HN0JB+IB_;J-7;98A@$ITEVZIBF`0
M$!`>?PM7;EB[&_:;C=A)237:FG5/[&>Q>LV]19G8O)2M3BXR3[&FJ-/TIBN'
M8S&)\*;`YNQ"<AR%QKE6]4UL0X"!P80=B?M(WN[O43#'D2$1^Z/KS6';666=
MVYH,SVO5:2U<?IG!.7WU,?MV8?\`\?W-K\)2D=+J[MI>B$Y17W(XUS[9'B8/
MCW@GEEWIU'A6`"+EUG[&ZI1[1.":+&P-I%TL<I>@_#1:M#F,/T``=>0OJ/J(
M:78&9OW/86.O+^,&DOM;1/.E^FN:SJ'A=/:]N61L/[(W(M_P2;&:',LS6H3R
M^Y:Q%/8B\S^XR<RW739Y)L%.R[6G:I1*G)0-ZHE==&<-3"``H@SG6KYD(A]"
MK4Y?N<`[M[4#8BH8%\O6.(2[2K2%B\_XTR#@R'D'HD3;!=9\L/:*='G<'Z%1
M6GYFHEC6X=0^*[>))AZF#@#:3@!P".6WN>Z3J[J]GO8/(DPR@ZCB?%=RM\B]
M?*%326<Q\,Z"'B4`-ZKR,[-*-V+5$O4Z[EPFF4!,8`X`BGFI1:;F9::<$(FO
M+R;^473)^T(M(.E7:A"=0`>PIU1`/[G`-A/BUQ58:U[8'S4Y:DV1VT'E.R0$
M#67"B0$&01QJ;'Z4LZ0.)0.LU3DK<9`#`(D!5%0H?6*<``QQ\`V0ZE^S\R_M
M=K%@39>(W=QK3XS.V*:5E-C5)##=HEGU=;7.$:3:,,[E&]X9(2#B/3=@F=8B
M*13F*(@4`X!\6V/LW-MM?M?,EYGQ7L?1-D+;CF!6M!,-UC&5DJEKN$-&&!Q/
MHU5^]M$ZV?V%A$E5<MH_X(*2!DA02-\8Z9#@8YE4E$5%$5DSHK(G.DJDJ0R:
MB2B9A(=-0AP`Q#D,`@("`"`AP!E[[:/QU>&#+&$J-NI@VH6;+NS-#<1T1DB*
MV%L,/;IG`.6&[--=P>LTB'BX:J-H^2,0[ROSB[-V[4:CU360<I+I(@;..`'`
M%;GO+/TJ='_)2QI_"_(O`(>^UE_3@:A_XJV!_P"G3*G`&\O`#@"-/R,_I`]X
M?RN-B_QN6[@%]7@"]O\`8!\O.O.;<PY;SCE[%DUB[,R&-8R)QW'TUW%R,6K1
MZ]:!D7Q[)%2#H'_S<R=/HF8J8)IE]!$1$`+ZOU)+2O\`IA;/?_1,6?[-\`@S
MY+?:>:IZ/Z);+[84K9W8"XVK!^/5+C!UBSQ..T:_,O23,1&`SE%8J#:R*;44
MY$QA%)0IP$H?<].`81>`:_O<;8DG!\<W@3SNBBLK6D].8'$DBX*41;L)Q;&N
M*[C#(KGZ="K2S!!^9(.OUBLE/V.`9:];<G(83V'P3F)VB9PTQ5F'&N1'C<B8
MJG794VXPUA>()IAZG45;1YBE`/41$.`/8:#>JKD^C4[)%%F6=BI=^J\%<JG/
M1RR;AC,URRQC68AI-HLD8Y%$'L>\34*("/H;@'K>`'`$S_N!]DJAM3Y<MPLF
M8_EF=@I$3=8?%U<GX\Q5&,VWQ/582@R<FR7(4J;I@YGX)V+=<HF(NW`BA3"4
MP<`L&]GYBZR77RZQU[BVBYZ_AO7[+]HM#\J8BV;DM#&-QW#LU5A#L*X>R-K[
MTR=>\Y6Z@@`E(;H!FXSSZYRS/UZB/^]?(OJ/J(__`'?,?2(_2/`-('@C]O7C
M/R_:\Y?S7=]DKUA:0QGF(,8M(&JT2`M3.49_@;7;0,LY>2\U&+-W(K3@H@F0
MIB]J8#UZCT`"\?\`4?M?_P"GMF+^)RE?[6\`/U'[7_\`I[9B_B<I7^UO`-#7
MAR\1-*\/N&\KX>I&9[3FICE3)K?)3R:M55B*HZAW;>K1%7"+:M8B2DTG3<Z,
M2545#G*8#'$.G0.H@98/?(_ON\;/^CFU?^4]?>`9+_$S^DYT&_*SP9^,"$X`
M[OX!2YYF?-#@7Q'X2&7GSL,A;*9`BI%/!N"6C\B;^;>I%.V"YW=1`XNJWC6#
M>B'S+H2@L^5*+5H!E1.=$!1YFS-&P^^FS%ERSDR3L&8-A,^79B14D;''=2D_
M8)91I!UJJU>!CDS`W8L6Q&L=&,&Y.U%NDDD4!Z=1`_)OV/\`8C2C/[RG7J$O
M>`=B<(VR,?*,U5G%>NM'M489I-0DM&R4<X$R2I2G0=,WC58Z2J9B*)G,0P"(
M#/'V\GGYJ_DJH,=K7L;,Q=:WCQW73*NE50:141L)5H<I4U;S4FQ!2;HW2.:]
MAIZ(2*'J!GK4ORQEDF@&HO@!P##_`.XGUC>8QVOK>P\0P.6G["UAJA*NTD>U
MNUR30V36&E&JQPZ@"LK5BQ[D@CZJ&36Z!T)R^/TU;JAE=H7=M7I?SN-NMQ3?
M%V;K<HM?EN<\7X)Q\3/GZH]HW,3O&UNBQ'^1R=I*32X*_:2A)/\`-#Y<EXOF
M\#/=RQY5\.#R:6O!UY68C!ZT=IWL7821F+9V74'#>0)=QV1]`L$RZ%1S2;"\
M6'L95&=D%A59.3B"3!XH<B@@BL!D:N]>ND5_/QGO7;-IRRUN'\S9BN-Z$5PN
MP2[;D%PDNV<4FO65)6U^GKK+8P+CL;=%U1Q-R;>FO2?"S.3XVYM]EN<G6,GP
MA)NOJRK'9HFHFLF15(Y%4E2%4253,4Z:B9R@8AR'*(E.0Y1`0$!Z"'*1--.C
MX-%[TU)<T>*8N"\M#5FS\D&W23$Q3(J91.Z4$J0I`#Q[7X-V_*)3"(F,5ZLH
M`F^@X_6#Z>:;='ISGTQPSN=JTE/L4YI?<EZ#*SK7&$.JN;5OC']Y7[7"#E][
M?I*[N=).6E]7M[-;93*^Z"N;7L:HI2==:M)RZLBJD86:M]N;![6ZK%IJ"44S
MO&\8O(/^@>J?RY##TZEZU[^H_=%K#['_`.Q6YI:[)W8QY4^/RK34[DO0Y<D/
M/F?F63^F+:EW,[[>X+D&]!B[4I\U.'SKL7;MQ\W1SGY<J\4;I^4#-$S+9[E'
MP;V#R;XPK&PVMK5@;;W`M<D(5A57:[:.;9NQD9TXF5:(63='1:,+G7Y1PNZ@
MU7!R-EQ=.&BQR?%151`5PVZFY7U_R6]JUWK=XQ#EK'%B1%Y"V"-F*;=Z=9H-
MZ1PU<"V>),9:*DH]\V*J@L4"F*8I3D-]`\`V4:,>\[SSB6B5_'F[6OK39)S7
MHUO%)9CH-K:8\R/-H-021;O;E7WT)*5*PS(-B""SIJ:)%RI]\4*)Q.8X%C=A
M][KJ,VBEEJGI5L=,S@%'Y>/L-QQE68I0_8(@"TQ&OK:\1+W^G4K$X]/7I]S@
M&6#RZ>X+V[\L<<RQA9(JOX+UIAIEO/L\)41\^D_PFG(]10T3.9(M\@DU?VQY
M$E/W-6J:#*-;+??0;F6`JI0(5>.;Q<;<>3O,,1C#7+'LFXK:<FT1R'F2<8/&
M6+,6PAU""^E[/9#)E:+OT&HB=M%-3*R3Y3H1)+H)CE`9(^3;43$_C[]MCL[J
MIBD52TK$^O$/`?;DBDBC*6ZV3F3Z>[L=MF"MB_"++W&W2RSDY"]2)"N5(H]A
M"\`4L<`=I>'/]%1X]/R1<&_P$A^`63<`6]>ZA\&!\&6VR^2O5&G=F&;].@]V
M<QY7&0_+XMO\\[`HY5AXUJ02M*'>I1?I*D3*5*+F5@5``0>=K<#.!XH/)WF7
MQ4[5UO8'&9W,_39,K:KYMQ4H^.UA\HXV7>I.)"(6`PF;M+)$'*+N&?F(8S)Z
M4.O<@JNDH`X[U1VGPINI@''&RNOMN:W+%^38-&8AGR8D2DHIX7[S,5>RQQ5%
M%86U5J2(HSD&:@]Z#A(P`)B"4Y@)$\`5N>\L_2IT?\E+&G\+\B\`A[[67].!
MJ'_BK8'_`*=,J<`;R\`.`(T_(S^D#WA_*XV+_&Y;N`;W?9)?S'=O?RK67XH:
M/P#:?P"G+W!'Z&;R"?\`(Y7^%M8X`F4X`WL<>.K'?E#\!NIVK-ZDB5B7E=1]
M;[9B[(`,A?KX]RA6\70*E9LGRA%$57D6J5RLQD6Y3E,O'/%R%$JG88H"N#=_
M0+:?QY9CF\+;0XNG:/-L7SQ*NVCY-TZH.1(=NX42;6;']N*@2*L<,^2("@`F
M<'+?N^&Y215`R90+CO$C[FK;/QF8_A=?+G38?9_6>O+K#4:39Y]Y5KWC5D[<
MJ.WL10KZBPFR$KBCE8ZJ<9(L7J#90YOEC($$Q!`T;L?>YZ=J1*:TGIALLTG!
M;F,K',;1BZ1B2.NWJ5%.9<3$6\4;B?T%06!#`'K\,?HX!3MY(O=[;0;68WM>
M%-3<2L]2J-=8MY7[3D!S;37O-$A7Y%NJSE(RO3+:'KT!1`E&J@IJN6K=W())
MG,5!RD</B"!E0PG@G,VR>2*_B/`^-+EEO)EL>I,X2GTB%>3LR\565(D+A8C8
MADF$>@90#+NW)T6K<G4ZJA"`)@`;)>WJ\-8^)S66==Y45B)C;#/Z\-/YHD(9
MPE(P]*B(1)W^".*:_*)!V2;:MC).7$B]3'X3R2<J`F)T$$#B`IJSS_[Y9F_Y
MKY$_A?,<`8Q>R:_F&[6?E8__`(DH'`-G_`#@!P!?![Y']]WC9_T<VK_RGK[P
M#)?XF?TG.@WY6>#/Q@0G`&L'F7\Q6#_$CKXXM]C6B;QL5?8]^SP#@D)`49*W
M2Z0@V6MEI!KWO(+&M874`[]Z($,Z5*#-L(KJ"*8"B':'9_/.[F?;ML)L!<97
M(^7,FS17$@].F?Y=JD8X-X6J52$0[T(6MPC8Q&L='MB@1%(H``&.8QC`,/\`
MVS_M^T]1H"M;\;CU(AMH;=#`^PKB^>:=PZ_5*<8]H62>8N"_>\O66.=&(*9R
M]T"R4^$'1VJO\$"8ON*?!="^3K#_`/OVP/#1<1NYAJO+IU=P7X,>CG&CL16?
M+8KLSL130^W&AU%5JZ_6_O#DYFBARMW'>B`K`KECRYK;E^-LE;DKAB#-F&KL
M#EA(-1?5JZT&]U&4.DHF=-0J+V,EXB3:'2705+])3IJ%$HF*(#7KP'>=W'WE
M7Q0EC+*KJO4+=W&4(B;(%&;JIQ\7E>!8)(H'RSC9DL8!%LX4$/MF)2,HI$.3
M=Y>K15(Q0-%W`(2^0;3FM[QZQWG"DL9I'V@Z);+C*S.4N\:OD.$265@'YE"A
M\4D<_%0[%\!?4S-RIZ"8"\G?3C>VJV%NK3YVSS2TE>2_!>_9DUSKPYH\)P_%
M%=U2`=3-C:3J%M+48"]RQU=/F6+C7Z=Z*?(_'EE5PG3W9/OH+?,CXYO&(+Y:
M\89*KLA4[W2)IW`6:OR:1DG<?),C]AP#K]5=HY3Z*MUB"9)=`Y5"")3`/-.,
M9DM!FL?9RN*N1O8^_!3A./%23_XKL:?%---)JAE5E\3D,%DKV(RMJ5G(:>;A
M<A)4<9+^U/M354TTTVG4\7SWJ'S3Y6S5P_=-H]DU</WSY=-HS8,VZKMX]<KG
M!-%JU:($47<N%CF`I2$*8QA$``.?F4HVX.Y<:C;BJMMT22[6V^"2[ZG]+=NY
M=FK=J+E<DTDDJMM\$DEQJV;A?"=">3*D8Z0A]IHUA#:R1\`HXQXWRX\?HYT@
M6Z;4%8]I#LR`NY:45)$`$&\^9%RV2Z?*@"0=G*&==;_2W7Y)WMIRE/=4KE+S
MTZ7[6;KZSD^"=WSLU4G[?'B:&=`=/U9Q^+5C>$8PVG&U6RM0VM7!4]507%JU
M^&]1Q7L>KP,@NXN56^<-K]C,M,E2KQM\S%>YN'6(83I*09IQVUA#HG$3=4#Q
M35$4_7]H(<N;LK$3P.T,9A[BI=T^BM1DN_FY$Y5\^9LH[OW,1W!O3*9JVT[.
MIUUZ<6N*<.=\G_+0\SK_`*\9AVBR5!8FPC2I6Z6Z=>-VY_DVRX0U?9K'Z+SM
MKF02,QK\"P2`RBSAP8H=I1`@&.(%'V]Q[EPNTL7<S.=OPL:.W%OBUS3:[(6X
M]LYOL45Z71<3T]L;6SN[\M;PV`T\[^MN22X+U8)]L[DNR$%Q;D^'"G%T0Q2T
M#TPIFBFN56PK65D)B?[SV3)-R(W^`M<K[*(H%F)3M.'QDXMF1!-FP1,/5)F@
MGU#O$XCFKU$WQKNH&YKV=U2<--[%BW7A;LQ;Y8^',ZN4VNV3=.%#4;IML/0=
M.]K6<!I&IZGV[]VE/FWI)<TO'E5%&"?9&*KQ;)J\@I/@X!$':30/2_=:,1B]
MI]:\39I%HE\"/FK;5F1[;$H]IB@E#W2/!C;8E$.[KV-WJ9!,`"("(!P"D2_^
MT3\-US=N7<'2,]XN!R8Q_E:!G&9<-&YS&[C"V2R)$W\R91'Z"=PD*'H``'3@
M'-&_LUO$FBNDJI;MQG:::A3G;.,QX_*@N4H]125,UPPV<@F</01(H0W3Z!`>
M`2[PC[7SPR82?MI8-87N6I9J!.UWFS(UUOC)0Z9@.11>LA*Q-.6-W!Z@,=VF
M#T$!#TX!>ECO&F.L15*+H.*:'3L:T>#2^##T^AUJ'J59C$Q`H&!C"0+-A&MA
M/VAW"1,!,/J(B/`.>;/ZT8>W$P/D36O/U<=V[$&5(V.B;M76,].5AW)L8F>B
M;,Q21GJV_BYN.,C,0C97N;N$S&`@E$1*8P"!25^JE^$/^B_<?SBM@?Y1^`7O
M82PWC_7C$.-<%8HAUZ_C3$E,K^/Z)".922FG$55JQ'(14,P6EYET^E9)1LR;
MD**SA95900ZF,(CUX!U'@'F[E3JKD.I6:AWFOQ-LIER@I6L6NL3S)&1A;!7I
MQDM'2\/*L')3H.V$@Q<'253,`@8AA#@&?E?VJ'A$7667'5NV)BLJHJ*:&PV?
MTD4Q4.8XIHI$R,!$DB=W0I0]"E``#@%F&A_C/U*\:];NU,U$J=TH--R#+L;#
M8JG.Y6R1D*N_;[%J9B$W$1=\LUA;0,H]9?#1=K,P1,[301!7O^$GV@3ZX!4M
MN]X0?'#Y$\NL,Z;888L&0,E1E/BJ(SFXO+.4Z0W3K,*]DY".8FB*9;8.*441
M=2[@PK&1%4P'Z&,(```!XK4GV_\`XM]'L]TO9C6_!%DI>8L?HV1"K6.0S-E^
MVM&"=LK,O4)P%(&U727@WHNH"<<HE%9N<4Q4[R=#E*8`+GN`'`*",F^V0\-^
M7\CW[+%\UNMDK>,FW.S7^XRB&?,Z1B$E:+?,O)^??HQL;D!K'1Z;N4?JJ`B@
MDFBD!NTA2E```"P[0[QOZC^-6@W3&>H&/97'5.R#<$[W:8V5O-UO:KZRI0L?
M7R/4G]WG9Y\R2"+C$2?!14(EU*)NWN$1$"=/`.);'Z\8HVQP?D?73.4`YM.)
MLL0`UF\5]G-S-;=2D.9XT?BV1G*\^C9J-/\`-,DS?$;KI*?5Z=>@B'`*/?U4
MOPA_T7[C^<5L!_*/P"^S$F+*5@[%N/,-8VC%H7'V+*96Z!28=Q(/Y9>+JU3B
M6L)!L%925<.Y.04:1S),@K.%5%E!+W',)A$>`?GYAP;AG8.F/L=YTQ7C_+]%
MD@-\W5,CU*#N$&=0Q!(#E)A.,GJ+9ZF`_>UT@(LF/02&`0`>`43YA]JUX8LM
MRCN9::]6W$;]X?O5##V6;O6XL@B7IVM*[-R%GK3$G7U[46:8=1_8Z``$8C^S
M3\2ICF,6Y;E)E,8Q@3)F+'0D(`B(@0HJ84.H)2AZ!W&$>GTB(\`[3C'VE7AI
MQY(-)*9Q;F'+2K,Z*J;?)V:[,I'JJ(@4!%W'4)"A,WA%A*(G35(=(1,/0H!T
M``+R-;=-=4]/:XK5-7]?<4X.AG)"DD"X^I\3"2<P!3BH09ZP)H'G[`<AQZE,
M]=+F*/T"'`)+\`SSV'VM'A6M$_.6::UFM[J9L<Q)STLY)L)GMN1Q)S#U>0?K
M$;M\AI(($5=.#F`A"E(4!Z```'`+--$?'+J5XV,>W#%NH6/93'5+O=Q_#RS1
MDK>+I>UGUG^QHZ`^>3D;O.SS]HG]EQ2"?P4E")=2=W;W"(B!.3@!P`X!6]OU
MXF=&?)L]Q=(;CXLF<D.L-M;>SQ^I$Y'R%00B&]Z5K:]F(N2BV6ODE/GE*FQ$
MHN05%'X0_#[>\_4"'.'?;2^'W`V5L=9JQCKG:H/(F*KE7[[29ASGC.$RWC+/
M6))"6AGRT3+WUY%R*;5\V(<47"2B*G3H8H@(AP#H.U/M^O&)NOFVV[#[,XFR
M3E#*]S4;!*3\IL/G1DT91S!(&\9`5V"BK\Q@ZS6XI#J5LP8-T&J7<8P$[SG,
M8#S6OWMP?$!K-F&BYUQ?JXL&0\;S!+#3W5TRIE?(<#%SS=-0L?,'JEUN4W6W
M\A$K'!PS4<-51;.DR+)]JB9#`!>7P`X!3'MG[?OQ3;L9NLVQ.?=;#S&6;HA'
M$M]BJ&2LFXX;V5Y&-_E$)N9@Z);("$>V%=H0B;E^9O\`-.@2(*ISF+UX!S_"
M/MN/$QKAEBB9QPCA7)>.LJXTL#.STRXU_9'/R,C$2K,3!U[%<AK-7K%ZV44;
MNVJZ:K9VU5416(=,YBB!>YP`X!3IY2?$I0=^85&_TR0B\;[*UB,^1A+HNT,,
M#>XEL41:5/(B;),SU5NU'J#"22*HY8=PD$BR(_#+VOI-UBR/3N^\=KHSU6U[
MLJRM)^O:D^VY9KPJ_?@Z1EVUC+B^&=8.BV,ZDZ=9+0RAI=UV84A=:]2[%=EN
M]15HO<N).4.RDH\%F[P1X`]Z<FY)E:IE.$K^"*/6I4&,WD.<EXRUI32!>U05
M\>PE>D5'-E*N@/4BSE2/;$,/:<X*%,F%G-P?43L#%8R&LQ%RYD-?=C6%F$96
M^5_]:<XTA3PBIR[TJ-,JMMOZ:.H.5RT]'F86\=CK4Z2O3E&YSKQLPA)N=>YM
MQCQHY)IHU4Z5^*G4G2)LTEJ)3QO.4R(D*]R_D9)C.W`%Q`OQOP<3^53BJ:T,
M<OU21Z*2PD'M465'J8:C[YZN[QWY.5G(7_V^(;X::S6%NG=S\>:X_.;:\(HN
M/L+HYLKI_&-_&V/W&82XZF_2=VO?R<.6TOR).G"4I'./+SMK+X-U]>80P_'3
M5SV?V;82F.L5T6FL7DW;FL)*I?9MPO*<1%(N)`C2(C79FS57M(4S]PF(&[4E
M1+]+HSL^SG]QQSV:E"QM7%2C>U%VXU&VY1?-;M<TJ*LI+FDO@3X5:K\SK9O.
M_M_;,MOX.%R_NW+1E9L6K2<KBA+U;EWEBG*D8MQBTO;DGV1E2D72/VZF1[N$
M+>=T+,KB^JJ%;O28?I;UG(9%DT1^$J5K:;00'<'4"*)F$%$FGS[P!ZE,9`P=
M>=YWW]2^,T'/C]CVOW>KXK]S=35F+[*PAPE<\G+DC^9%?.G_`-+N4R#MY+?E
MUZ32<)?MK33O27!TN3XPM5XIJ//*GP,U=8'UQPCK)2&>/,%XWK6.JPU32!9O
M!L2$D)=PD3L^T;!,K?%EI^45ZB)W#M9941$?4`].5"W!N;.[JU\LEG]5=U.K
MEWS?"*^&$5ZL(^"BDBY>W-K;?VECXXO;NEM:7212X07K2:]Z<W64Y/OE)MG;
M>?")`'`#@!P`X`<`.`'`#@!P`X`<`.`'`#@!P`X`<`.`'`#@!P`X`<`.`'`#
M@!P`X`<`.`'`#@!P`X`<`.`'`#@!P`X`<`.`'`#@!P`X`<`.`'`*^\0_SY-C
M/_:C][U2_?1_.9_\HK_\$_\`Y_\`_EG_`*WX_.CYK_T'&?UGZES]/^A[?>_W
MGQ_AY3F>#_\`H65_HOT[7ZG]?V/V?]G_`)?X^8L$YS@Z8'`#@!P`X`<`.`'`
M#@!P`X`<`.`'`#@!P`X`<`.`'`#@!P`X`<`.`'`#@!P`X`<`.`'`#@!P`X`<
7`.`'`#@!P`X`<`.`'`#@!P`X`<`__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
